ORIGINAL ARTICLESSwedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
References (22)
Effects of salicylates on human platelets
Lancet
(1968)- et al.
Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease
Thromb Res
(1983) - et al.
Physiologic variables affecting thromboxane B2 production in human whole blood
Thromb Res
(1985) Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease
Lancet
(1990)Aspirin all round?
Br Med J
(1988)Secondary prevention of vascular disease by prolonged anti-platelet therapy
Br Med J
(1988)- et al.
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls
N Engl J Med
(1979) - et al.
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
J Clin Invest
(1982) - et al.
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
J Clin Invest
(1983) - et al.
Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
N Engl J Med
(1983)
Cited by (698)
A mechanistic model to study the kinetics and toxicity of salicylic acid in the kidney of four virtual individuals
2021, Computational ToxicologyAntiplatelet Therapy for Secondary Prevention of Stroke
2021, Stroke: Pathophysiology, Diagnosis, and ManagementRepurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy
2021, Seminars in Cancer BiologyAdherence to study drug in a stroke prevention trial”?>
2020, Journal of Stroke and Cerebrovascular DiseasesBleeding risk assessment for stroke patients on antithrombotic therapy
2019, Clinica e Investigacion en Arteriosclerosis
- 1
Coordinating centre: Division of Clinical Pharmacology, Danderyd Hospital (C-E. Elwin, B. Peterson). Steering committee: C. Blomstrand, J-E. Olsson, B Nilsson, M. von Arbin, M. Britton, C-E. Elwin, C Helmers, B. Norrving, A. Rosén, K. Samuelsson, K. Strandberg, N. G. Wahlgren Adjudication committees: Stroke: K. Samuelsson, C. Blomstrand, A. Gårde, B. Norrving, J-E. Olsson, Death: M. Britton; Myocardial infarction: M. von Arbin, A. Carlsson, C. Helmers, Compliance: C Blomstrand, C-E. Elwin, A. Rosén, J. Svensson; Adverse effects: N. G. Wahlgren Safety monitoring committee: B. Huitfeldt, P. O. Lundberg, L. Wilhelmsen. Statisticians: H. Melander, I. Selinus. Correspondence to Dr Bo Norrving, Department of Neurology, University Hospital, S-221 85 Lund, Sweden.